Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone adjunctive therapy in CDKL5 deficiency disorder
2018-001180-23Phase 3Unknown
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jul 2018
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ganaxolone in CDKL5 deficiency disorder (CDD) and epilepsy (3 arms), sponsored by Marinus Pharmaceuticals. Primary endpoints: Primary efficacy endpoint and Primary seizure types. Status: unknown.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)epilepsy
Beyond the preview
Go deeper on 2018-001180-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001180-23.